Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Adverse Drug Reactions
Galderma Wins FDA Approval for Vectical Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
February 20th, 2009
Galderma Laboratories, L.P. announced that the U.S. Food and Drug Administration (FDA) has approved Vectical™ (calcitriol) Ointment 3mcg/g, a unique vitamin D3 product for the treatment of mild-to-moderate plaque psoriasis in adults. Psoriasis is a chronic skin disorder that affects 2 to 3 percent of the U.S. population. It is characterized by thick, red, scaly patches of skin and caused by an abnormally high growth rate of skin cells that form thick, dry scales (plaques). The disease is also associated with other serious conditions such as diabetes, heart disease and obesity. Vectical™ Ointment is the only vitamin D3 ointment of its kind...
Source: Health Business Week (2009-02-20)
|
